Business Context and Reporting Period
This Form 8-K was filed by MEI Pharma, Inc. on November 8, 2017. The report details a corporate event regarding a new equity financing arrangement. Note: The request metadata lists "Lite Strategy, Inc.", but the filing text explicitly identifies the registrant as MEI Pharma, Inc.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the authorization of a potential capital raise of up to $30,000,000 through an At-The-Market (ATM) Equity Offering Sales Agreement.
Material Changes
On November 8, 2017, the Company entered into a Sales Agreement with Stifel, Nicolaus & Company, Incorporated. This agreement allows the Company to sell up to $30,000,000 of its common stock through the sales agent. Sales may occur via ordinary brokerage transactions on the Nasdaq Capital Market, block transactions, or other methods agreed upon. The Company will pay the sales agent a commission of up to 3% of the gross sales price per share.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks beyond the standard terms of the Sales Agreement. The offering is subject to the Company's shelf Registration Statement on Form S-3 (Reg. No. 333-217645). The text notes that the description of the agreement is qualified by reference to the full Sales Agreement included as Exhibit 1.1.
Investor Verification Checklist
- Verify the exact number of shares issued and total proceeds raised under the ATM program since November 8, 2017.
- Review the full Sales Agreement (Exhibit 1.1) for specific termination rights and volume limitations.
- Confirm the current share count and dilution impact on existing shareholders.
- Check subsequent filings for any actual sales activity or changes in the sales agent.